Adults with insulin-treated type 2 diabetes benefit from automated insulin delivery systems regardless of their C-peptide ...

When the core set of symptoms are the same, how can you tell diabetes type 1.5, or LADA, apart from it's famous cousins?

VIENNA — Two experts from the UK who spoke at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting offered advice for avoiding misdiagnosis of adults who present with diabetes ...

Tzield, a monoclonal antibody approved for stage 2 Type 1 diabetes, now seeks approval for stage 3 disease based on trial ...

A RECENT Greek study presented at EASD 2025 has suggested that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor ...

Peptides have become an increasingly important area of research in numerous scientific fields, especially for their diverse functions.

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot ...

A machine learning–driven web tool based on 13 standard patient metrics demonstrates strong predictive performance for MASLD, ...

GLP-1RA use was associated with a lower incidence of rheumatic diseases such as rheumatoid arthritis, gout, and ...

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations ...